K36 Therapeutics Receives FDA Clearance for First-in-Class Multiple Myeloma Drug KTX-1001
Key Insights
K36 Therapeutics (search) received FDA clearance for its Investigational New Drug application for KTX-1001, a first-in-class methyltransferase inhibitor targeting MMSET (search) in multiple myeloma (search) patients.
The company plans to initiate a Phase 1 clinical trial in the second half of 2022, enrolling approximately 50 patients with relapsed and refractory multiple myeloma (search).
KTX-1001 specifically targets patients with the t(4;14) genetic translocation, addressing a significant unmet medical need in high-risk multiple myeloma (search) treatment.
K36 Therapeutics (search) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for KTX-1001, a first-in-class methyltransferase inhibitor designed to treat patients with relapsed and refractory multiple myeloma (search). The Cambridge-based biotechnology company achieved this regulatory milestone just 16 months after its founding in February 2021, marking its transition to a clinical-stage company.
Novel Mechanism Targets High-Risk Patients
KTX-1001 represents a novel approach to multiple myeloma (search) treatment as a potent and selective inhibitor of multiple myeloma SET domain (MMSET (search)), a major regulator of chromatin structure and transcription in multiple myeloma. The orally administered small molecule specifically inhibits the catalytic activity of lysine H3K36 (search) methyltransferase, with particular focus on patients carrying the t(4;14) genetic translocation.
"There remains a significant unmet need for new and more effective therapies that can benefit high-risk myeloma patients such as those with translocation t(4;14)," said Dr. Noopur Raje, Director of the Center for Multiple Myeloma (search) at Massachusetts General Hospital Cancer Center. "As we use expanded combinations in early lines, there is a need for new classes of agents like KTX-1001."
Phase 1 Trial Design and Patient Population
K36 plans to initiate a Phase 1 clinical trial in the second half of 2022, designed as a single-arm, open-label study in patients with relapsed and refractory multiple myeloma (search). The multi-part clinical trial will feature dose escalation followed by an expansion cohort specifically recruiting patients with the t(4;14) genetic translocation. The company expects to enroll approximately 50 patients to evaluate the safety, tolerability, and preliminary efficacy of different doses of KTX-1001.
The trial design reflects the precision medicine approach, enriching for patients who carry the specific genetic abnormality that the drug is designed to target. This strategy addresses a population with particularly poor prognosis despite recent therapeutic advances.
Expert Advisory Board Formation
Concurrent with the FDA clearance announcement, K36 established a Clinical Advisory Board comprising seven world-renowned multiple myeloma (search) experts: Dr. Jesus Berdeja from Sarah Cannon Research Institute (search), Dr. Shaji Kumar from Mayo Clinic, Dr. Thomas Martin from University of San Francisco, Dr. María-Victoria Mateos from University of Salamanca, Dr. Noopur Raje from Harvard Medical School, Dr. David Siegel from Hackensack University Medical Center, and Dr. Suzanne Trudel from University of Toronto.
"BCMA T cell redirecting therapies and the use of quadruplet therapy in myeloma are incredible advances but still have not leveled the playing field for high-risk multiple myeloma (search) patients," noted Dr. Jesus Berdeja, Director of Myeloma Research at Sarah Cannon Research Institute (search). "There is still a need for novel precision therapeutics such as KTX-1001, and we are excited to be a part of bringing this first-in-class agent into Phase 1 testing."
Company Background and Leadership
Founded in February 2021, K36 Therapeutics (search) is backed by prominent investors including F-Prime Capital, Atlas Venture, and Eight Roads Venture Capital. The company's mission focuses on translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics for cancer patients worldwide.
"We are proud to announce the clearance of our first IND following the initial 30-day FDA review, officially marking our transition to a clinical-stage company in only 16 months since company inception," said Dr. Terry Connolly, President and Chief Executive Officer of K36. "This achievement demonstrates our team's efficiency and focus toward our goal of advancing KTX-1001 and positively impacting the lives of patients and families suffering from multiple myeloma (search)."